Omnio Raises €2.9M for Chronic-Wound Therapy

Omnio’s financing is a small but relevant biotech signal in an area with meaningful clinical and economic burden.

What happened

Swedish biotech Omnio raised an oversubscribed €2.9 million round from existing investors and shareholders. The funding will support development of its plasminogen-based therapy for hard-to-heal chronic wounds as it moves toward clinical studies.

The company is focused on using plasminogen biology to support tissue repair and wound healing.

Why it matters

Chronic wounds are a significant healthcare problem, especially in ageing populations and patients with conditions such as diabetes or poor circulation. They can be painful, expensive to manage and difficult to resolve with standard care.

Omnio is still early-stage, so this is not a major clinical proof point yet. But it is a watchlist signal in a field where better therapies could have substantial patient and health-system impact.

The bigger picture

Biotech funding is increasingly selective, but focused therapeutic approaches for clear unmet needs continue to attract support. Omnio’s raise shows that smaller European biotech rounds can still move forward when the target indication is specific and clinically meaningful.